Nucryst appoints interim CEO
This article was originally published in Scrip
Executive Summary
Nucryst Pharmaceuticals (US) has appointed David Holtz interim president and chief executive officer, and Neil Carragher chairman. Mr Holtz, who remains CFO, succeeds Thomas Gardner, who was chairman, president and CEO. Mr Carragher was formerly Nucryst's lead director.